Relay Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage precision medicine company that transforms drug discovery by integrating computational and experimental technologies via its proprietary Dynamo platform to target previously intractable protein motion for small-molecule therapeutics in precision oncology and genetic diseases. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company advances a pipeline including RLY-2608, a pan-mutant selective PI3Kα inhibitor in Phase 3 (ReDiscover-2) for PIK3CA-mutated, HR+/HER2- metastatic breast cancer and Phase 2 (ReInspire) for PIK3CA-related vascular malformations; RLY-8161, an NRAS-selective inhibitor for NRAS-driven solid tumors advancing toward clinical development in the second half of 2025; αGal, a program for Fabry disease with clinical start planned for the second half of 2025; and lirafugratinib (RLY-4008), an FGFR2 inhibitor globally outlicensed to Elevar Therapeutics. Relay Therapeutics operates primarily in the United States with international clinical trial reach and maintains ongoing collaborations with D.E. Shaw Research for computational modeling, Pfizer for RLY-2608 combination therapies in breast cancer, and Elevar Therapeutics, which includes a late 2024 licensing deal providing up to $500 million in milestones and low-teens royalties. Recent advancements encompass disclosure of three new preclinical programs in June 2024 targeting vascular malformations, Fabry disease, and NRAS; positive Phase 3 progression-free survival data for RLY-2608; and a cash position of $596.4 million as of September 30, 2025, supporting operations into late 2026 amid cost-saving measures.
Company News
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Is Relay Therapeutics a Buy After Promising Trial Results?
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Why Relay Therapeutics Stock Popped on Wednesday
Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise
Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Relay's treatment shown to shrink vascular malformations in mid-stage trial